Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
WALTHAM, Mass., Dec. 20, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time), in San Francisco, California.
To access the live webcast of the presentation and following breakout session please visit the Investors section of the AMAG website at www.amagpharma.com. A replay of the presentation will be archived on the AMAG website until February 9, 2018.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
